MedTrace Logo

Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core

NCT07791810 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2026-08-28

No results posted yet for this study

Summary

an investigator initiated, prospective, multicenter, randomized, open-label, blinded endpoint trial (PROBE)

Conditions

Interventions

PROCEDURE

Patients assigned to the EVT group should undergo EVT as soon as possible, followed by BMM according to the current EVT guidelines.

EVT should be performed as soon as possible in patients randomized to the EVT group. Investigators and clinicians should make every effort to minimize delays related to pre-procedural preparation, with a target interval of no more than 60 minutes from randomization to arterial puncture. EVT in the EVT group can be performed with any thrombectomy device (NMPA approved) usually used at study site.

DRUG

The medical group receives BMM alone. EVT is not performed in the medical group.

The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to current AIS management guidelines but may NOT include any intra-arterial therapies.

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Principal Investigators

  • Huaizhang Shi, MD, PhD · The First Affiliated Hospital of Harbin Medical University, China

  • Wei Hu, MD, PhD · The First Affiliated Hospital of USTC (Anhui Provincial Hospital), China

  • Jianmin Liu, MD, PhD · Changhai Hospital, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-18
Primary Completion
2028-04-18
Completion
2028-04-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07791810 on ClinicalTrials.gov